Login to Your Account


Gilead Sciences rides Sovaldi launch for strong first quarter; Amgen falls short

By Jennifer Boggs
Managing Editor

Thursday, April 24, 2014
The eagerly awaited earnings season kicked off this week, but investors hoping for first-quarter sales data to restore stability to the selloff-plagued biotech sector are unlikely to see a quick fix as the drug pricing debate continues to garner headlines. But promising pipeline opportunities should keep the top four big biotechs on steady ground in the year ahead.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription